InMed Pharmaceuticals Inc. (INM) News
Follow InMed Pharmaceuticals Inc. (INM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
InMed had a Pre-IND meeting with FDA on INM-901
InMed said it held a Pre-IND meeting with the FDA for its INM-901 program. The company also said it is integrating FDA feedback into its development planning.
MACRO | Sep 09, 2026, 10:02 PM UTC
L
InMed Pharmaceuticals FY Loss Cont Ops $2.84/Shr
InMed Pharmaceuticals FY Loss Cont Ops $2.84/Shr
EQUITY | Sep 09, 2026, 10:00 PM UTC
L
InMed Pharmaceuticals FY Loss/Shr $3.12
InMed Pharmaceuticals FY Loss/Shr $3.12
EQUITY | Sep 09, 2026, 09:59 PM UTC
L
InMed Pharmaceuticals reports fiscal 2026 revenue of $3.18M and EPS loss of $3.12
The company reported fiscal 2026 revenue of $3.18 million, largely from discontinued BayMedica commercial operations. Net loss attributable to common shareholders was $13 million, and diluted loss per share was ($3.12).
EARNINGS | Sep 09, 2026, 08:48 PM UTC
L
INM reports FY 2026 net loss of $12.6M after revenue operations ceased
INM reported a $12.6 million net loss for FY 2026 and said its cash reserves are expected to fund operations into Q3 2026. The company wound down its only revenue-generating segment and said its future depends on a pendi
EARNINGS | Sep 09, 2026, 08:35 PM UTC
L
InMed reports full-year fiscal 2026 financial results and corporate update
EQUITY | Sep 09, 2026, 08:31 PM UTC
H
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
() -- InMed Pharmaceuticals (INM) entered into an amendment to its definitive merger agreement for an all-stock transaction with Mentari Therapeutics and its subsidiaries that clarifies details of the deal, the company s
MNA | Jul 07, 2026, 07:40 AM UTC
H
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
InMed Pharmaceuticals announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company
MNA | Jul 06, 2026, 11:01 PM UTC